Skip Navigation LinksHome > March 2013 - Volume 23 - Issue 3 > HSP60 Predicts Survival in Advanced Serous Ovarian Cancer
International Journal of Gynecological Cancer:
doi: 10.1097/IGC.0b013e318284308b
Ovarian Cancer

HSP60 Predicts Survival in Advanced Serous Ovarian Cancer

Hjerpe, Elisabet MD*; Egyhazi, Suzanne PhD; Carlson, Joseph MD, PhD; Stolt, Marianne Frostvik BT; Schedvins, Kjell MD§; Johansson, Hemming BSc*; Shoshan, Maria PhD; Åvall-Lundqvist, Elisabeth MD, PhD*

Collapse Box


Objective: Heat shock protein 60 (HSP60) plays an essential role in malignant cell survival. We evaluated the prognostic and treatment predictive value of HSP60 in advanced ovarian cancer.

Methods: Fresh tumor samples were prospectively collected from 123 patients undergoing primary surgery for suspected advanced ovarian cancer. Of these, 57 fulfilled the eligibility criteria, that is, International Federation of Gynecology and Obstetrics stage IIC-IV, serous/endometrioid tumors, platinum-based chemotherapy, and specimens with 50% tumor cells or greater. Heat shock protein 60 mRNA and protein expression was determined by real-time polymerase chain reaction and immunohistochemistry. We estimated the association between HSP60 and overall survival (OS) and platinum-free interval (PFI) by Cox proportional hazards models and its relationship with treatment response by Fisher’s exact test. Median follow-up was 60 months.

Results: High HSP60 mRNA expression was associated with shorter OS (hazard ratio [HR], 3.4; 95% confidence interval [CI], 1.3–8.5) and PFI (HR, 3.3; 95% CI, 1.5–7.2). Likewise, high HSP60 protein expression was associated with shorter OS (HR, 3.2; 95% CI, 1.5–7.1) and PFI (HR, 2.6; 95% CI, 1.3–5.3). Median survival for patients with high HSP60 protein expression was 31 months compared with 55 months for low expression cases (P = 0.016). The impact on OS and PFI was even stronger in the subgroup of grade 3 serous tumors. All patients with low HSP60 levels responded to first-line chemotherapy.

Conclusion: Heat shock protein 60 may identify groups of advanced serous ovarian cancer with different prognosis and treatment response.

Copyright © 2013 by IGCS and ESGO


Article Tools


Article Level Metrics

Search for Similar Articles
You may search for similar articles that contain these same keywords or you may modify the keyword list to augment your search.

Connect With Us


For additional oncology content, visit LWW Oncology Journals on Facebook.